Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 3, 2026 · Filed Mar 5, 2026
Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,115,577
Shares × reported transaction price
29 days after results of Feb 2, 2026, 63 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $635.54 on Mar 3, 2026, 76% above its 52-week low and 17% below its high, after an 11% drop over the previous 30 trading days
52-week range $361.04 (Apr 8, 2025) to $766.68 (Nov 25, 2025), 68% of the way up, from 251 adjusted closes. 30 trading days earlier: $715.37 on Jan 16, 2026. Describes the past only, not a forecast
RSI 43, at its 200-day average, 5% under its 50-day average, 17% below the 52-week high, 20-day volatility 31% a year, against the S&P 500: −4 points over 1 month, −15 points over 3 months, −7 points over 6 months
From the adjusted closes up to Mar 3, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Nimrata Hunt is named in IDXX's executive-change filing of Mar 24, 2026, 21 days after this trade: "On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on…"
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −5.7% | −1.5% | −4.2% |
| 30 days | −5.1% | −2.0% | −3.1% |
| 90 days | −7.2% | +12.6% | −19.8% |
| 180 days | −11.4% | +13.8% | −25.2% |
Past results only. Not a forecast.
Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Mar 3 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Feb 12 · filed 20 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: changed a top executive or board member, 18 days earlier (Feb 13, 2026). The first one after it: changed a top executive or board member, 21 days later (Mar 24, 2026).